[A26-44] Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Addendum to Project A25-155
Last updated 05.06.2026
Project no.:
A26-44
Commission:
Commission awarded on 29.04.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation; adjuvant treatment
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-44
| Project no. | Title | Status |
|---|---|---|
| A25-155 | Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
05-06-2026 A G-BA decision was published.
G-BA documents on this decision